Advanced Filters
noise

Tualatin, Oregon Clinical Trials

A listing of Tualatin, Oregon clinical trials actively recruiting patient volunteers.

Found 618 clinical trials
G GV20 Therapeutics

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

18 years of age All Phase 1/2
S Site Public Contact

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal …

18 years of age All Phase 2
M Maya Fajardo

Distal Radius Interventions for Fracture Treatment

This protocol describes a multicenter, prospective randomized superiority trial comparing functional outcomes between children treated with sedated reduction versus no formal reduction.

4 - 10 years of age All Phase N/A
W Wesley Stoller, MA

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Pembrolizumab will be administered at a dose of 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Enzalutamide will be administered at dose of 160 mg orally every day. All patients will be required to have at least one high-risk criteria.

18 years of age Male Phase 2
S Samantha P Martin, MA

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group …

18 years of age All Phase 4
S Site Public Contact

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of …

60 years of age All Phase 3
W Women's Health Research Unit

Vestibulectomy Surgical Techniques Comparison Study

Vestibulectomy Surgical Techniques Comparison Study

18 - 80 years of age Female Phase N/A
A Ahmad Masri, Dr

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1) Establish the diagnostic accuracy of 124I-evuzumitide in cardiac amyloidosis 2) Evaluate extracardiac uptake 3) identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid …

40 - 90 years of age All Phase 2
S Sarah Siegel

Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination

The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are: how does prior vaccination affect antibody responses to re-vaccination? how does prior vaccination affect the immune cell …

20 - 49 years of age All Phase 1/2
R Ruth Kraft

North American Prodromal Synucleinopathy Consortium Stage 2

This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

18 years of age All Phase N/A

Simplify language using AI